Table 1.
Drug concentrations and Targets. The following references were used to determine the drug concentrations used: (a) (Di et al., 2003), (b) (Sharon et al., 1997), (c) (Ogasawara et al., 2016), (d) (Davis et al., 2003), (e) (Ricciardi et al., 2005), (f) (Khomula et al., 2017), (g) (Gnegy et al., 2004), (h) (Kotturi et al., 2003), (i) (Hoffman and Johnston, 1998), (j) (Iannazzo et al., 1999), (k) (Jin et al., 2009), (l) (Liu et al., 2018), (m) (Bisogno et al., 2006).
| Drug | Target | Conc.(Ref.) | Source |
|---|---|---|---|
| Extracellular application | |||
| Dex-cyclodextrin | GR | 1 μM(a) | Sigma |
| WIN 55,212-2 | CB1 agonist | 5 μM(a) | Tocris |
| AM251 | CB1 antagonist | 4 μM(a) | Sigma |
| Bis(indolylmaleimide) | PKC inhibitor | 1 μM(b) | Sigma |
| DO34 | DAGL Inhibitor | 1 μM(c) | Cravatt Lab |
| U0126 | ERK inhibitor | 10 μM(d) | Sigma |
| PD 0325901 | ERK inhibitor | 100 nM(e) | Tocris |
| Xestospongin C | IP3R antagonist | 1 μM(f) | Sigma |
| Thapsigargin | ER Ca ATPase | 5 μM(g) | Sigma |
| THL | Lipase inhibitor | 25 μM(m) | Sigma |
| Nifedipine | V-gated Ca2+ block | 10 μM(h) | Sigma |
| PP1 | SRC inhibitor | 10 μM(d) | Tocris |
| Intracellular application | |||
| 8-Br-cAMP | PKA activator | 100 μM(i) | Sigma |
| SC-10 | PKC activator | 500 nM(j) | Sigma |
| PKC19-31 | PKC inhibitor | 10 μM(k) | Sigma |
| BAPTA | Ca2+ chelator | 40 mM(g) | Sigma |
| m3M3FBS | PLC activator | 10 μM(l) | Tocris |